Join NAMSA for an educational and engaging webinar that explores the widely unknown topic of biofilm. We discuss the serious health threat of biofilms to global health, the relationship between antimicrobial resistance (AMR) and biofilm and the In Vitro biofilm test models that reflect real-world challenges products face.
In nature, 80% of bacteria exist within a biofilm. When microorganisms live beneath a biofilm, they are significantly less susceptible to antimicrobial agents, antibiotics and the host’s immune system.
As it relates to medical device development, standard microbiological testing focuses almost exclusively on planktonic bacteria. This focus may lead to an underestimation of the quantity of active agent required to remove a microbial biofilm effectively. This is why testing against biofilms In Vitro is critical during preclinical development. If this step is skipped, it could lead to products failing during In Vivo testing or clinical trials.
Attendees of this webinar can expect to walk away with a better understanding of the following:
- Biofilm basics-what they are and why they are an important consideration in preclinical testing
- How biofilms impact medical device products
- Various biofilm test models and recommendations